3/21/2012 | CVHYPF | AVI BioPharma files $100 million shelf for stock, debt and preferreds
|
7/31/2009 | CVHY | AVI BioPharma files $125 million shelf for debt, preferreds, stock
|
1/30/2009 | PP | New Issue: AVI aims for $16.5 million in direct offering of shares
|
12/13/2007 | PP | New Issue: AVI negotiates $20.3 million direct offering of units
|
12/13/2007 | PP | Market Commentary: Skygold plans C$3.12 million; EnerLume gets $1.1 million; AVI negotiates $20.3 million
|
11/8/2006 | BT | AVI's quarterly net loss up at $6.8 million, revenues fall to $13,000
|
10/30/2006 | BTCV | AVI files $75 million shelf
|
10/4/2006 | BT | Market Commentary: Acorda off on $31.5 million deal; Dynavax up 13%; Advancis up 8%; AVI falls 7%; Exelixis at bat
|
10/4/2006 | BT | Market Commentary: Acorda off on $31.5 million deal; Dynavax up 13%; Advancis up 8%; AVI falls 7%; Exelixis at bat
|
9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
8/9/2006 | BT | AVI says Neubiotics block, eliminate bacterial targets
|
8/9/2006 | BT | Market Commentary: Palatin up; Genaera gouged by reverse split plans; Onyx off; RegeneRx up; KOS up
|
8/8/2006 | BT | AVI BioPharma reports net loss of $6.9 million for second-quarter 2006
|
8/3/2006 | BT | AVI adds two patents to cardiovascular program development
|
7/20/2006 | BT | AVI BioPharma modifies hepatitis C study
|
6/5/2006 | BT | AVI BioPharma reports Esprit technology effective against diabetes in mice
|
5/24/2006 | BT | AVI BioPharma gets patent allowance for antibacterial technology
|
5/10/2006 | BT | AVI BioPharma data shows benefit to hepatitis C patients
|
5/10/2006 | BT | Market Commentary: Alnylam gains as bird flu names slip; AVI pushes vaccine names lower; Novacea ends flat on debut
|
5/9/2006 | BT | AVI details confirmatory studies, preliminary efficacy data for Neugene antisense compounds
|
4/20/2006 | BT | AVI BioPharma's release of data from hepatitis trial delayed
|
3/30/2006 | BT | AVI BioPharma's Neugene inhibits influenza A, studies say
|
3/21/2006 | BT | Market Commentary: Novavax, Nastech buck uptrend in flu names; NitroMed exec exits applauded; BioMarin off on deals
|
3/13/2006 | BT | AVI BioPharma, Cook in agreement to develop Neugene drugs for vascular diseases
|
3/8/2006 | BT | AVI BioPharma gets government funding for viral research, sees net loss tighten by 33% in 2005
|
1/27/2006 | BT | AVI and Chiron form license agreement for hepatitis C virus
|
1/20/2006 | BT | AVI confirms efficacy of Neugene against multiple flu strains
|
1/13/2006 | BT | AVI BioPharma's Neugene shows success against Ebola virus
|
1/10/2006 | BT | AVI BioPharma's results favorable for hepatitis C study
|
11/14/2005 | BTPP | New Issue: AVI BioPharma sells $22.6 million stock in direct placement
|
10/21/2005 | BT | AVI BioPharma announces progress in developing Neugene against avian influenza
|
10/14/2005 | BT | AVI BioPharma announces favorable results from Ebola, Marburg, ricin, anthrax programs
|
1/19/2005 | PP | New Issue: AVI BioPharma plans $24 million direct placement of shares
|
1/19/2005 | PP | Market Commentary: U.S. private placement volume remains weak; Western Canadian plans big deal
|